Top

Published in:

01-02-2008 | Preclinical Study

Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility

Authors: Karin Milde-Langosch, Stanislava Janke, Ines Wagner, Christine Schröder, Thomas Streichert, Ana-Maria Bamberger, Fritz Jänicke, Thomas Löning

Published in: Breast Cancer Research and Treatment | Issue 3/2008

Abstract

Fra-2 (Fos-related antigen 2) is a member of the Fos family of AP-1 transcription factors which is often up-regulated in mammary carcinomas. Previous results suggested that it might be involved in the regulation of breast cancer invasion and metastasis. In order to analyze the role of Fra-2 in breast cancer cells, it was silenced in the highly invasive MDA-MB231 cells using RNA interference. On the other hand, stable transfectants of the weakly invasive MCF7 cell line were established in order to analyze the effects of Fra-2 overexpression. In both approaches, cell proliferation was not or only weakly influenced by Fra-2. In contrast, the invasive potential of the cells was increased, and a weaker effect on motility was observed. By cDNA microarray analysis of the MCF7 transfectants followed by validation on a protein level, we identified several Fra-2 target genes which might be involved in cell invasion and migration, i.e., ALCAM and connexin 43. Additionally, mRNA expression levels of various genes which are associated with a more malignant behavior of the tumors in vivo were up- or downregulated, i.e., members of the MAGE family, S100P, TIMP2, IL24 etc. These results show that Fra-2 overexpression is associated with a more aggressive tumor phenotype and is probably involved in breast cancer progression in vivo.

Karin M, Liu Z-G, Zandi E (1997) AP-1 function and regulation. CurrOpinCell Biol 9:240–246

Tulchinsky E (2000) Fos family members: regulation, structure and role in oncogenic transformation. Histol Histopathol 15:921–928PubMed

Milde-Langosch K (2005) The role of the Fos family of transcription factors in tumorigenesis. Eur J Cancer 41:2449–2461PubMedCrossRef

Nishina H, Sato H, Suzuki T et al (1990) Isolation and characterization of fra-2, an additional member of the fos gene family. Proc Natl Acad Sci USA 87:3691–3623CrossRef

Matsui M, Tokuhara M, Konuma Y et al (1990) Isolation of human fos-related genes and their expression during monocyte-macrophage differentiation. Oncogene 5:249–255PubMed

Gruda MC, Kovary K, Metz R et al (1994) Regulation of fra-1 and fra-2 phosphorylation differs during the cell cycle of fibroblasts and phosphorylation in vitro by MAP kinase affects DNA binding activity. Oncogene 9:2537–2547PubMed

Wisdom R, Verma IM (1993) Transformation by fos proteins requires a C-terminal transactivation domain. Mol Cell Biol 13:7429–7438

Bamberger A-M, Methner C, Lisboa BW et al (1999) Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive phenotype. Int J Cancer 84:553–558CrossRef

Kustikova O, Kramerov D, Grigorian M et al (1998) Fra-1 induces morphological transformation and increases in vitro invasiveness and mobility of epithelioid adenocarcinoma cells. Mol Cell Biol 18:7095–7105PubMed

10.

Andersen H, Mahmood S, Tkach V et al (2002) The ability of Fos family members to produce phenotypic changes in epitheloid cells is not directly linked to their transactivation potentials. Oncogene 21:4843–4848PubMedCrossRef

11.

Milde-Langosch K, Röder H, Andritzky B et al (2004) The role of the transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas. Breast Cancer Res Treat 86:139–152PubMedCrossRef

12.

Milde-Langosch K, Bamberger A-M, Goemann C et al (2001) Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. J Cancer Res Clin Oncol 127:537–544PubMedCrossRef

13.

Nandy A, Jenatschke S, Hartung B et al (2003) Genomic structure and transcriptional regulation of the human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (PGDH) gene. Endocrinology 31:105–121

14.

Vial E, Sahai E, Marshall CJ (2003) ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer cell 4:67–79PubMedCrossRef

15.

Rajagopalan D (2003) A comparison of statistical methods for analysis of high density oligonucleotide array data. Bioinformatics 19:1469–1476PubMedCrossRef

16.

Belguise K, Kersual N, Galtier F et al (2005) Fra-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene 24:1434–1444PubMedCrossRef

17.

Tkach V, Tulchinsky E, Lukanidin E et al (2003) Role of the Fos family members, c-Fos, Fra-1 and Fra-2, in the regulation of cell motility. Oncogene 22:5045–5054PubMedCrossRef

18.

Acquaviva C, Ferrara P, Bossis G et al (2001) Degradation of cellular and viral Fos proteins. Biochimie 83:357–362PubMedCrossRef

19.

Sonobe MH, Yoshida T, Murakami M et al (1995) Fra-2 promoter can respond to serum-stimulation through AP-1 complexes. Oncogene 10:689–696PubMed

20.

Otte M, Zafrakas M, Riethdorf L et al (2001) MAGE-A gene expression pattern in primary breast cancer. Cancer Res 61:6682–6687PubMed

21.

Taback B, Chan AD, Kuo CT et al (2001) Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay:correlations with clinical stage of disease. Cancer Res 61:8845–8850PubMed

22.

King JA, Ofori-Acquah SF, Stevens T et al (2004) Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res 6:R478-R487PubMedCrossRef

23.

Rabeneau KE, O’Toole JM, Bassi R et al (2004) DEGA/AMIGO-2, a leucine-rich repeat family member, differentially expressed in human gastric adenocarcinoma:effects on ploidy, chromosomal stability, cell adhesion/migration and tumorigenicity. Oncogene 23:5056–5067CrossRef

24.

Laird DW, Fistouris P, Batist G et al (1999) Deficiency of connexin 43 gap junctions is an independent marker for breast tumors. Cancer Res 59:4104–4110PubMed

25.

Qin H, Shao Q, Curtis H et al (2002) Retroviral delivery of connexin genes to human breast tumor cells inhibits in vivo tumor growth by a mechanism that is independent of significant gap junctional intercellular communication. J Biol Chem 277:29132–29138PubMedCrossRef

26.

Shao Q, Wang H, McLachlan E et al (2005) Down-regulation of Cx43 by retroviral delivery of small interfering RNA promotes an aggressive breast cancer cell phenotype. Cancer Res 65:2705–2711PubMedCrossRef

27.

Rakha EA, Boyce RW, Abd El-Rehim D et al (2005) Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 18:1295–1304PubMedCrossRef

28.

De Bruin A, Muller E, Wurm S et al (1999) Loss of invasiveness in squamous cell carcinoma cells overexpressing desmosomal cadherins. Cell Adhes Commun 7:13–28PubMedCrossRef

29.

Tselepis C, Chidgey M, North A et al (1998) Desmosomal adhesion inhibits invasive behavior. Proc Natl Acad Sci USA 95:8064–8069PubMedCrossRef

30.

Wolverton T, Lalande M (2001) Identification and characterization of three members of a novel subclass of protocadherins. Genomics 76:66–72PubMedCrossRef

31.

Schmidt A, Jäger S (2005) Plakophilins - hard work in the desmosome, recreation in the nucleus? Eur J Cell Biol 84:189–204PubMedCrossRef

32.

Papagerakis S, Shabana AH, Depondt J et al (2003) Immunohistochemical localization of plakophilins (PKP1, PKP2, PKP3, and p0071) in primary oropharyngeal tumors: correlation with clinical parameters. Hum Pathol 34:565–572PubMedCrossRef

33.

Arumugam T, Simeone DM, Van Golen K et al (2005) S100P promotes pancreatic cancer growth, survival and invasion. Clin Cancer Res 11:5356–5364PubMedCrossRef

34.

Carlsson H, Petersson S, Enerback C (2005) Cluster analysis of S100 gene expression and genes correlating to psoriasin (S100A7) expression at different stages of breast cancer development. Int J Oncol 27:1473–1481PubMed

35.

Brummer O, Athar S, Riethdorf L et al (1999) Matrix-metalloproteinases 1, 2 and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch 435:566–573PubMedCrossRef

36.

Remacle A, McCarthy K, Noel A et al (2000) High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 89:118–121PubMedCrossRef

37.

Peters MG, Farias E, Colombo L et al (2003) Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model. Breast Cancer Res Treat 80:221–232PubMedCrossRef

38.

Porter S, Scott SD, Sassoon EM et al (2004) Dysregulated expression of adamalysin-thrombospondin gens in human breast carcinoma. Clin Cancer Res 10:2429–2440PubMedCrossRef

39.

Umetani N, Mori T, Koyanagi K et al (2005) Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene 24:4721–4727PubMedCrossRef

40.

Tsuchiya T, Okaji Y, Tsuno NH et al (2005) Targeting Id1 and Id3 inhibits peritoneal metastasis of gastric cancer. Cancer Sci 96:784–790PubMedCrossRef

41.

Inoue A, Omoto Y, Yamaguchi Y et al (2004) Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells. J Mol Endocrinol 32:649–661PubMedCrossRef

42.

Bahassi EM, Karyala S, Tolinson CR et al (2004) Critical regulation of genes for tumor cell migration by AP-1. Clin Exp Met 21:293–304CrossRef

Title: Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility
Authors: Karin Milde-Langosch
Stanislava Janke
Ines Wagner
Christine Schröder
Thomas Streichert
Ana-Maria Bamberger
Fritz Jänicke
Thomas Löning
Publication date: 01-02-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9559-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

Detection of the CHEK2 1100delC mutation by MLPA BRCA1/2 analysis: a worthwhile strategy for its clinical applicability in 1100delC low-frequency populations?

Risk of neoplastic transformation in asymptomatic radial scar. Analysis of 117 cases

An overview of prognostic factors for long-term survivors of breast cancer

Cardiotoxicity and anthracyclines

Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network

Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case–control study and a pooled meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer